FFEI Life Science has successfully concluded phase I of the BiognostiX project with a symposium to share the results of this 3-year EU funded FP7 research programme. Delegates to the event, held at the Hauser Forum, Cambridge, UK on Thursday 27 February.
Led by FFEI, the BiognostiX Consortium has developed a radical new approach to performing diagnostic tests at point-of-use, with potential applications in veterinary, agri-food and human diagnostics. The BiognostiX technology uses a multiplex microfluidic platform and newly invented Immuno-Ink to deliver fast, flexible, single-use tests in a format that anyone can use.
The test is performed on a BiognostiX Chip, which combines the desired biochemistry and microfluidics with a novel technology platform. A microfluidic channel is engineered on the paper-based surface of the chip and reagents are printed to specific zones of the channel using fluid-jet printing technologies, thus enabling simultaneous performance of multiple tests per sample.
The simplicity of this approach facilitates changes in assay configuration during the development process, which when optimized, can then be fixed for simple, low-cost manufacture.
George Hutchinson, Director, FFEI Life Science commented, “This has been an fascinating project to be involved with, particularly as the consortium has brought together teams from across Europe with different areas of expertise. We are delighted that we have now been able to demonstrate proof-of-principle and look forward to further collaboration to take this project forward.”